Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Topics

Select Topic

Showing 1,267 results.

Thumbnail for Golcadomide-A Potential First-in-Class Oral CELMoD Combined With Pola-R-CHP in Frontline Aggressive B-Cell Lymphoma: Safety and 12-Month Efficacy

ABCL - 142

Golcadomide-A Potential First-in-Class Oral CELMoD Combined With Pola-R-CHP in Frontline Aggressive B-Cell Lymphoma: Safety and 12-Month Efficacy

Muhamad Alhaj Moustafa

Poster Presenter: Muhamad Alhaj Moustafa

Thumbnail for Rising Mortality from Multiple Myeloma-Associated Heart Failure in Older US Adults: A CDC WONDER Analysis (1999-2024)

MM - 144

Rising Mortality from Multiple Myeloma-Associated Heart Failure in Older US Adults: A CDC WONDER Analysis (1999-2024)

Osama Mohiuddin

Poster Presenter: Osama Mohiuddin

Thumbnail for Venous Thromboembolism in Lymphoma: Risk Stratification and Evolving Anticoagulation Strategies

Previous 1...9 10 11 12 13 14 15...141 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

ABCL - 146

Venous Thromboembolism in Lymphoma: Risk Stratification and Evolving Anticoagulation Strategies

Swapnil Surpur

Poster Presenter: Swapnil Surpur

$Thumbnail for Overall Survival With Anti-BCMA Therapies: Indirect Comparison of Belantamab Mafodotin/Bortezomib/Dexamethasone (BVd) vs Teclistamab/Daratumumab (Tec-Dara) in Relapsed/Refractory Multiple Myeloma$

MM - 147

Overall Survival With Anti-BCMA Therapies: Indirect Comparison of Belantamab Mafodotin/Bortezomib/Dexamethasone (BVd) vs Teclistamab/Daratumumab (Tec-Dara) in Relapsed/Refractory Multiple Myeloma

Moshe Levy

Poster Presenter: Moshe Levy

Thumbnail for CRISPR/Cas9-Mediated SHP2 Knockout in Jurkat T Cells Using Neon and MaxCyte Electroporation Platforms: Establishment and Validation of a Model for SHP2-Driven Resistance Mechanisms

AML - 150

CRISPR/Cas9-Mediated SHP2 Knockout in Jurkat T Cells Using Neon and MaxCyte Electroporation Platforms: Establishment and Validation of a Model for SHP2-Driven Resistance Mechanisms

Kashif Ali

Poster Presenter: Kashif Ali

Thumbnail for Mortality Trends in Older Adults With Myelodysplastic Syndromes and Cardiovascular Disease: A CDC WONDER Analysis (1999-2025)

MDS - 154

Mortality Trends in Older Adults With Myelodysplastic Syndromes and Cardiovascular Disease: A CDC WONDER Analysis (1999-2025)

Priyanka Keshav Lal

Poster Presenter: Priyanka Keshav Lal

Thumbnail for Low-Dose Nivolumab Combined With AVD Chemotherapy for Advanced Hodgkin Lymphoma: Interim Results of a Phase 2 Trial

HL - 155

Low-Dose Nivolumab Combined With AVD Chemotherapy for Advanced Hodgkin Lymphoma: Interim Results of a Phase 2 Trial

Mobil Akhmedov

Poster Presenter: Mobil Akhmedov

Thumbnail for Divergent Global Trends in Myelodysplastic Neoplasms in the Survivorship Era: GBD 2023 Analysis of Rising Incidence, Disproportionate Mortality, and Widening Survival Gaps

MDS - 156

Divergent Global Trends in Myelodysplastic Neoplasms in the Survivorship Era: GBD 2023 Analysis of Rising Incidence, Disproportionate Mortality, and Widening Survival Gaps

Tapan Giri

Poster Presenter: Tapan Giri

Thumbnail for Global Burden and 2045 Projections of Diffuse Large B-Cell Lymphoma: HDI-Based Survival Disparities in the CAR T-Cell and Bispecific Era (GLOBOCAN 2022)

ABCL - 157

Global Burden and 2045 Projections of Diffuse Large B-Cell Lymphoma: HDI-Based Survival Disparities in the CAR T-Cell and Bispecific Era (GLOBOCAN 2022)

Tapan Giri

Poster Presenter: Tapan Giri

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors